Market:

Dengue virus is a mosquito-borne pathogen prevalent in tropical areas of Southeast Asia, the Caribbean, Latin America, and Africa. Currently, the permissible habitat of these virus-spreading mosquitoes is ever-expanding due to the impact of climate change, with the continental United States and Europe becoming emergent areas of viral spread. It is expected that half of the global population – over 4 billion people – will likely be exposed to these mosquito vectors by the year 2050. According to the World Health Organization, there are 390 million Dengue virus infections per year with 3.9 billion people at risk of infection, hospitalizing approximately 500,000 and killing about 2.5% of those infected. The target market of our Dengue virus vaccine expands to all of those at risk of exposure to the virus – nearly 4 billion people globally.

Development Stage:

• Pre-clinical

Patents:

• "VACCINES TO PREVENT ZIKAVIRUS AND CORONAVIRUS INFECTIONS", developed by Prof. Vaithilingaraja Arumugaswami et al. of the University of California, Los Angeles, PCT/US2022/030282

Select Publications:

• Coming soon

Team:

• Gustavo Garcia, Jr: Co-Founder and Chief Executive Officer
• Dr. Sanjay J. Chauhan, M.D.: Founder and Chief Medical Officer
• Dr. Vaithi Arumugaswami, DVM, PhD: Co-Founder and Chairman

Contact:

Website: www.veergen.com
Email: info@veergen.com
LinkedIn

Back to Top